medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2013, Number 1

<< Back Next >>

Salud Mental 2013; 36 (1)

Registro Electrónico de Adherencia al Tratamiento de Esquizofrenia en Latinoamérica (e-STAR): Resultados clínicos del uso de risperidona inyectable de liberación prolongada a dos años de seguimiento

Apiquian R, Córdoba R, Louzã M, Fresán A

Language: Spanish
References: 53
Page: 19-26
PDF size: 249.24 Kb.


ABSTRACT

Schizophrenia is a chronic psychiatric disorder associated to high healthcare costs mainly driven by inpatient care. Lack of adherence to antipsychotic treatment is a common reason for relapse and rehospitalization leading to poor prognosis and global functional impairment of patients. Risperidone long-acting injection (RLAI) has demonstrated its efficacy in treating symptoms of schizophrenia and offers the potential to improve adherence to treatment.
Objective: To determine clinical and functional efficacy of RLAI and use of health resources (eg., hospitalizations) in a 2-year follow up study among patients with schizophrenia from Latin America.
Method: The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is an observational study of patients who start treatment with RLAI. Data from patients recruited in Mexico, Colombia and Brazil were collected retrospectively for one year prior to baseline, at baseline and every three months for 24 months. Hospitalization rates and treatment regime were registered. Efficacy was assessed using the Clinical Global Impression of Illness-Severity Scale (CGI-S), while the Global Assessment of Functioning (GAF) and the Personal and Social Performance (PSP) were used for the evaluation of functioning.
Results: Seventy-three patients completed the two-year follow-up. The proportion of patients hospitalized declined from 16.4% before treatment to 4.1% after 2 years of treatment with RLAI. Only 2.7% discontinued the treatment due to lack of efficacy. Significant improvements were reported in illness severity as well as in global functioning assessed by the CGI-S, GAF and PSP scales, respectively.
Discussion: Our results give further support of the efficacy of RLAI for the treatment of schizophrenia. Additional to symptom severity reduction and functional recovery, improved treatment adherence and reduced hospitalization rates were observed with the use of RLAI. In a real world clinical setting, RLAI offer an effective long-term treatment for patients with schizophrenia, with a lower use of healthcare resources.


REFERENCES

  1. Organization for Economic Co-operation Development. París: Policy Brief. 2008.

  2. Cabello H, Díaz Castro L, Arredondo A. Costo-efectividad de intervenciones para esquizofrenia en México. Salud Mental 2011;34:95-102.

  3. World Health Organization. Disease control priorities related to mental, neurological, developmental, and substance abuse disorders. Ginebra; 2006.

  4. Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull 2004;30:279-293.

  5. Olivares J, Peuskens J, Pecenak J et al. Clinical and resource-use outcomes of risperidone long-acting injection in recent and long-term diagnosed schizophrenia patients: results from a multinational electronic registry. Curr Med Res Opin 2009;25:2197-2206.

  6. Svarstad B, Shireman T, Sweeney J. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811.

  7. Valenstein M, Blow F, Copeland L et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-264.

  8. Lacro J, Dunn L, Dolder C, Leckband S et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909.

  9. Fenton W, Blyler C, Heinssen R. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651.

  10. Velligan D, Lam F, Ereshefsky L, Miller A. Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-667.

  11. Boaz TL, Constantine RJ, Robst J, Becker MA et al. Risperidone longacting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population. J Clin Psychiatry 2011; 72(8): 1079-1085.

  12. Lang K, Meyers J, Korn J et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv 2010;61:1239-1247.

  13. Liu-Seifert HAD, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;23(3):21.

  14. Perkins D. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-1128.

  15. Lieberman J, Stroup T. The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011;168:770-775.

  16. Olfson M, Marcus S, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007;33:1379-1387.

  17. West J, Marcus S, Wilk J, Countis L et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull 2008;34:995-1001.

  18. Keith S, Pani L, Nick B et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004;55:997-1005.

  19. Chang C, Tzeng D, Lung F. Treatment effectiveness and adherence in patients with schizophrenia treated with risperidone long-acting injection. Psychiatry Res 2010;180:16-19.

  20. Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005;15:111-117.

  21. Fleischhacker W, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64:1250-1257.

  22. Kane J, Eerdekens M, Lindenmayer J, Keith S. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132.

  23. Schmauss M, Sacchetti E, Kahn J, Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007;22:85-92.

  24. Taylor M, Currie A, Lloyd K, Price M et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008;22:128-131.

  25. Lindenmayer J, Parak M, Gorman J. Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response. J Psychiatr Pract 2006;12:55-57.

  26. Llorca P. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-247.

  27. Olivares J, Rodriguez-Morales A, Diels J et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry 2009;24:287-296.

  28. Willis M, Svensson M, Löthgren M, Eriksson B et al. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ 2010;11:585-594.

  29. Hofer A, Hummer M, Huber R, Kurz M et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000;20:699-702.

  30. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317:1181-1184.

  31. Peuskens J, Olivares J, Pecenak J et al. Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries. Curr Med Res Opin 2010;26:501-509.

  32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Cuarta edición. Washington, DC: 1994.

  33. Bech P, Malt U, Dencker S et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand 1993;87(supl 372):16-64.

  34. Endicott J, Spitzer R, Fleiss J, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976;33:766-771.

  35. Morosini P, Magliano L, Brambilla L, Ugolini S et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000;101:323-329.

  36. Apiquian R, Ulloa R, Herrera-Estrella M et al. Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophr Res 2009;112:181-186.

  37. Apiquian R, Córdoba R, Louzã M. Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month followup from the Electronic Schizophrenia Treatment Adherence Registry in Latin America. Neuropsychiatr Dis Treat 2010;7:19-26.

  38. Emsley R, Oosthuizen P, Koen L, Niehaus D et al. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008;23:325-331.

  39. Emsley R, Medori R, Koen L, Oosthuizen P et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008;28:210-213.

  40. Rabinowitz J, Napryeyenko O, Burba B et al. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol 2011;31:75-81.

  41. Lieberman J. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 2007;68:e04.

  42. Lieberman J, Stroup T, McEvoy J et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.

  43. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005;6:129-137.

  44. Gianfrancesco F, Rajagopalan K, Sajatovic M, Wang R. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006;144:177-189.

  45. Becker M, Young M, Ochshorn E, Diamond R. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Adm Policy Ment Health 2007;34:307-314.

  46. Rummel-Kluge C, Schuster T, Peters S, Kissling W. Partial compliance with antipsychotic medication is common in patients with schizophrenia. Aust N Z J Psychiatry 2008;42:382-388.

  47. Damen J, Thuresson P, Heeg B, Lothgren M. A pharmacoeconomic analysis of compliance gains on antipsychotic medications. Appl Health Econ Health Policy 2008;6:189-197.

  48. Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig 2010;30:777-787.

  49. Marcus S, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-180.

  50. Sun S, Liu G, Christensen D, Fu A. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-2312.

  51. Olivares J, Rodriguez-Martinez A, Burón J, Alonso-Escolano D et al. e-STAR Study Group. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53.

  52. Lambert T, Olivares J, Peuskens J, et al. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry 2011;10:10.

  53. Parellada E, Kouniakis F, Siurkute A, Schreiner A et al. Safety and efficacy of long-acting injectable risperidone in daily practice: an openlabel, noninterventional, prospective study in schizophrenia and related disorders. Int Clin Psychopharmacol 2010;25:149-154.




2020     |     www.medigraphic.com